← Back to Search

Monoclonal Antibodies

AL001 for Amyotrophic Lateral Sclerosis

Phase 2
Waitlist Available
Led By Sabrina Paganoni, MD
Research Sponsored by Alector Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help people with a certain form of ALS.

Eligible Conditions
  • ALS (Amyotrophic Lateral Sclerosis)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the curve concentration (AUC) for AL001
Change from baseline in CSF progranulin
Change from baseline in serum progranulin
+3 more
Secondary outcome measures
Change from baseline in CSF neurofilament light chain
Change from baseline in plasma neurofilament light chain

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AL001Experimental Treatment1 Intervention
AL001 every 4 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo every 4 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AL001
2018
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

Alector Inc.Lead Sponsor
10 Previous Clinical Trials
1,280 Total Patients Enrolled
Sabrina Paganoni, MDPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
161 Total Patients Enrolled
1 Trials studying Amyotrophic Lateral Sclerosis
137 Patients Enrolled for Amyotrophic Lateral Sclerosis
Katharine Nicholson, MDPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has AL001 gone through the regulatory process and been granted approval by the Food & Drug Administration?

"The safety of AL001 was rated as a 2 on our team's scale since there exists some evidence indicating it is safe, however no data attesting to its efficacy has been collected."

Answered by AI

Are any other locations in the state trialing this clinical research?

"This clinical trial is offered in 12 distinct locations, including the University of Michigan at Ann Arbor, Johns Hopkins University in Baltimore, and the University of Colorado in Aurora."

Answered by AI

Are there any vacancies available for potential participants in this clinical trial?

"As of this time, the clinical trial hosted on clinicaltrials.gov is not enrolling any new patients. This study was first announced in September 2021 and had its last update recorded back in April 2022. Luckily for those seeking treatments through trials, 539 other studies are currently recruiting people to take part."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
2021. "A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05053035.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top